Effect of the P2Y12 antagonist ticagrelor on neointimal hyperplasia in a rabbit carotid anastomosis model

Interactive Cardiovascular and Thoracic Surgery

Volumn 19, Issue 2, 2014, Pages 198-204

  Sürer, Süleyman ^a   Toktas, Faruk ^a   Ay, Derih ^a   Eris, Cuneyt ^a   Yavuz, Senol ^a   Turk, Tamer ^a   Vural, Ahmet Hakan ^a   Goncu, Mehmet Tugrul ^a   Gul, Nihal Yasar ^b   YalcInkaya, Ulviye ^b  

^a Bursa Yuksek Ihtisas Education and Research Hospital   (Turkey)

^b ULUDAG UNIVERSITY   (Turkey)

Author keywords

Carotid artery; Intimal hyperplasia; Rabbit model; Ticagrelor

Indexed keywords

PURINERGIC P2 RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; TICAGRELOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ADENOSINE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY ANASTOMOSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; IMMUNOHISTOCHEMISTRY; NEW ZEALAND WHITE (RABBIT); NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; ANALOGS AND DERIVATIVES; ANASTOMOSIS; ANIMAL; BIOPSY; BLOOD; CAROTID STENOSIS; DISEASE MODEL; DRUG EFFECTS; HYPERPLASIA; METABOLISM; NEOINTIMA; PATHOLOGY; RABBIT; RECURRENT DISEASE; SURGERY;

ADENOSINE; ANASTOMOSIS, SURGICAL; ANIMALS; BIOPSY; CAROTID ARTERIES; CAROTID STENOSIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; NEOINTIMA; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RABBITS; RECEPTORS, PURINERGIC P2Y12; RECURRENCE; TRANSFORMING GROWTH FACTOR BETA;

EID: 84905638072     PISSN: 15699293     EISSN: 15699285     Source Type: Journal    
DOI: 10.1093/icvts/ivu087     Document Type: Article

References (25)

1. O'Brien ER, Ma X, Simard T, Pourdjabbar A, Hibbert B. Pathogenesis of neointimal formation following vascular injury. Cardiovasc Hematol Disord Drug Targets 2011;11:30-9.
2. Merzkirch C, Davies N, Zilla P. Engineering of vascular in-growth matrices: are protein domains an alternative to peptides? Anat Rec 2001;263: 379-87.
3. Douglas JS Jr. Pharmacologic approaches to restenosis prevention. Am J Cardiol 2007;100:10-6.
4. Stadel JM. Thrombin: a versatile protease in restenosis. In: Feuerstein GZ (ed). Coronary Restenosis. New York, NY: Marcel Dekker; 1997:161-76.
5. Goncu T, Yavuz S, Cekirdekci A, Karaca I, Ozercan I. The effect of perindopril on the intimal hyperplasia occuring after vascular injury. Turk Gogus Kalp Dama 2001;9:109-14.
6. Reel B, Cavdar Z, Ergur BU, Ozkal S, Ozsarlak SG, Oktay G et al. Endothelin receptor independent correlation between HSP47 and collagen in rabbit model of early atherosclerosis. Turkiye Klinikleri J Med Sci 2011;31:1330-9.
7. Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995;92:3041-50.
8. Nesselroth SM, Willis SI, Fuse S, Olson ET, Lawler J, Sumpio BE et al. The C-terminal domain of thrombospondin-1 induces vascular smooth muscle cell chemotaxis. J Vasc Surg 2001;38:595-600.
9. Khan R, Agrotis A, Bobik A. Understanding the role of transforming growth factor-β1 in intimal thickening after vascular injury. Cardiovasc Res 2007; 74:223-34.
10. Husted S, van Giezen JJJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009;27:259-74.
11. Nigri GR, Kossodo S, Waterman P, Fungaloi P, La Muraglia GM. Free radical attenuation prevents thrombosis and enables photochemical inhibition of vein graft intimal hyperplasia. J Vasc Surg 2004;39:843-9.
12. Curcio A, Torella D, Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ J 2011;75:1287-96.
13. Gokalp O, Yurekli I, Mavioglu L, Kiray M, Bagriyanik A, Kestelli M et al. The effect of ascorbic acid on proliferation of vascular smooth muscle cells and intimal hyperplasia. Turkiye Klinikleri J Med Sci 2013;33:126-31.
14. Guzeloglu M, Reel B, Atmaca S, Bagriyanik A, Hazan E. The effects of PPARγ agonist rosiglitazone on neointimal hyperplasia in rabbit carotid anastomosis model. J Cardiothorac Surg 2012;7:57.
15. Wihlborg AK, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, Gudbjartsson T et al. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol 2004;24:1810-15.
16. Huynh TT, Davies MG, Trovato MJ, Barber L, Safi HJ, Hagen PO. Reduction of lipid peroxidation with intraoperative superoxide dismutase treatment decreased intimal hyperplasia in experimental vein grafts. J Surg Res 1999; 84:223-32.
17. Khurana R, Zhuang Z, Bhardwaj S, Murakami M, De Muinck E, Yla-Herttuala S et al. Angiogenesis-dependent and independent phases of intimal hyperplasia. Circulation 2004;110:2436-43.
18. Wolf YG, Rasmussen LM, Ruoslahti E. Antibodies against transforming growth factor-β1 suppress intimal hyperplasia in a rat model. J Clin Invest 1994;93:1172-78.
19. Sun D-X, Liu Z, Tan X-D, Cui D-X, Wang B-S, Dai X-W. Nanoparticlemediated local delivery of an antisense TGF-β1 construct inhibits intimal hyperplasia in autogenous vein grafts in rats. PLoS One 2012;7:e41857.
20. Um JW, Kim JM, Min BW, Kim YS, Son GS, Lee JB et al. Transforming growth factor-β1 expression and the role of angiotensin-converting enzyme inhibitor on perianastomotic intimal hyperplasia in polytetrafluoroethylene graft implanted in rabbit carotid artery. Kurume Med J 2004;51:235-43.
21. Li JM, Singh MJ, Itani M, Vasiliu C, Hendricks G, Baker SP et al. Recombinant human thrombomodulin inhibits arterial neointimal hyperplasia after balloon injury. J Vasc Surg 2004;39:1047-83.
22. Zurbrügg HR, Musci M, Sänger S, Gutersohn A, Mülling C, Wellnhofer E et al. Prevention of venous graft sclerosis with clopidogrel and aspirin combined with a mesh tubing in a dog model of arteriovenous bypass grafting. Eur J Vasc Endovasc Surg 2001;22:337-41.
23. Goncu T, Tiryakioglu O, Ozcan A, Ari H, Sezen M, Vural H et al. Inhibitory effects of ticlopidine and clopidogrel on the intimal hyperplastic response after arterial injury. Anadolu Kardiyol Derg 2010;10:11-6.
24. Steg PG, Harrington RA, Emanuelsson H, Katus HA, Mahaffey KW, Mejer B et al. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: An analysis from the prospective, randomized PLATO trial. Circulation 2013;128:1055-65.
25. Wang K, Zhou X, Huang Y, Khalil M, Wiktor D, van Giezen JJ et al. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. Thromb Haemost 2010;104:609-17.